Cyclopentylpyrazolamine Derivatives for Selective CDK2/Cyclin A Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for tumors associated with overexpression of cyclin-dependent kinases (CDKs, particularly CDK2, fail to selectively inhibit CDK2/Cyclin A activity, leading to uncontrolled cell proliferation and apoptosis imbalance.
Innovation Solution
A cyclopentylpyrazolamine derivative or its pharmaceutically acceptable salt, with specific structural components, is developed to selectively inhibit CDK2/Cyclin A activity, thereby regulating the cell cycle and inducing apoptosis in tumor cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for tumors associated with overexpression of cyclin-dependent kinases, then cell proliferation is inhibited, but selectivity for CDK2/Cyclin A is insufficient leading to uncontrolled cell proliferation
Solution Approach 1:
The patent applies local quality by designing a compound with specific structural features (cyclopentyl group at position 1, pyrazolamine core, and specific substituent patterns) that target CDK2/Cyclin A interaction interface. The compound selectively binds to CDK2/Cyclin A complex through optimized local molecular interactions, achieving high selectivity while maintaining effective inhibition of tumor cell proliferation.
2Reliability
If CDK2/Cyclin A activity is selectively inhibited to regulate cell cycle, then apoptosis is triggered in tumor cells, but sustained E2F activity leads to uncontrolled proliferation
Solution Approach 1:
The patent applies parameter changes by optimizing the compound's molecular parameters (substituent types, positions, and configurations) to achieve the right balance between CDK2 inhibition strength and selectivity. The compound parameters are tuned to sufficiently inhibit CDK2/Cyclin A to trigger apoptosis while avoiding excessive inhibition that would disrupt normal cell cycle regulation.
Data Source
AI summary
The present application belongs to the field of medicinal chemistry, relates to a cyclopentylpyrazolamine derivative and the use thereof, and specifically relates to a compound of formula (I), an isomer thereof, or a pharmaceutically acceptable salt thereof.